GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calliditas Therapeutics AB (OTCPK:CLTEF) » Definitions » PB Ratio
中文

Calliditas Therapeutics AB (Calliditas Therapeutics AB) PB Ratio : 12.42 (As of Apr. 25, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Calliditas Therapeutics AB PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-25), Calliditas Therapeutics AB's share price is $7.55. Calliditas Therapeutics AB's Book Value per Share for the quarter that ended in Dec. 2023 was $0.61. Hence, Calliditas Therapeutics AB's PB Ratio of today is 12.42.

The historical rank and industry rank for Calliditas Therapeutics AB's PB Ratio or its related term are showing as below:

CLTEF' s PB Ratio Range Over the Past 10 Years
Min: 2.53   Med: 5.51   Max: 20.95
Current: 16.09

During the past 9 years, Calliditas Therapeutics AB's highest PB Ratio was 20.95. The lowest was 2.53. And the median was 5.51.

CLTEF's PB Ratio is ranked worse than
94.27% of 1310 companies
in the Biotechnology industry
Industry Median: 2.38 vs CLTEF: 16.09

During the past 12 months, Calliditas Therapeutics AB's average Book Value Per Share Growth Rate was -56.30% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -36.40% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -16.90% per year.

During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Calliditas Therapeutics AB was 301.20% per year. The lowest was -36.40% per year. And the median was 3.10% per year.

Back to Basics: PB Ratio


Calliditas Therapeutics AB PB Ratio Historical Data

The historical data trend for Calliditas Therapeutics AB's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calliditas Therapeutics AB PB Ratio Chart

Calliditas Therapeutics AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only - 4.00 5.70 5.49 -

Calliditas Therapeutics AB Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.04 5.49 - - -

Competitive Comparison of Calliditas Therapeutics AB's PB Ratio

For the Biotechnology subindustry, Calliditas Therapeutics AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Calliditas Therapeutics AB's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Calliditas Therapeutics AB's PB Ratio distribution charts can be found below:

* The bar in red indicates where Calliditas Therapeutics AB's PB Ratio falls into.



Calliditas Therapeutics AB PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Calliditas Therapeutics AB's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=7.55/0.608
=12.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Calliditas Therapeutics AB  (OTCPK:CLTEF) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Calliditas Therapeutics AB PB Ratio Related Terms

Thank you for viewing the detailed overview of Calliditas Therapeutics AB's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Calliditas Therapeutics AB (Calliditas Therapeutics AB) Business Description

Traded in Other Exchanges
Address
Kungsbron 1, D5, Stockholm, SWE, SE-111 22
Calliditas Therapeutics AB is a commercial-stage biopharma company focused on identifying, developing, and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with unmet medical needs. The company's pipeline candidate is TARPEYO medication to reduce proteinuria in IgA nephropathy.